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Abstract: The postnatal period is a significant period of physical, physiological and psychological
change for mothers, rendering them particularly vulnerable to changes in mood or disorders such as
postnatal depression (PND). Previous interventions with foods high in flavonoids have demonstrated
beneficial acute and chronic mood effects in healthy child, adolescent and adult populations. It is
unclear whether mood effects persist in populations who are potentially at-risk of developing mood
disorders, such as postnatal mothers. This exploratory study investigated the effects of a 2-week
daily dietary flavonoid intervention on mood (PANAS-NOW), anxiety (STAI), depressive symptoms
(PHQ-8) and perceived quality of life (WHOQOL-BREF) in forty-one new mothers in the 0–12-month
postnatal period, before and after flavonoid intervention. Mothers either added high flavonoid foods
to their daily diet, or did not include additions following a randomised, between-groups, controlled
design. Significant effects were observed in the flavonoid group with mothers reporting lower state
anxiety and higher perceived quality of physical health at the 2-week timepoint. These findings
suggest that regular dietary consumption of flavonoids may benefit mothers’ anxiety and perceived
quality of life in the postnatal period. Replication of these results may indicate the potential for
dietary flavonoids to promote healthy mood regulation in mothers or prevent the onset or severity
of symptoms in postnatal psychological disorders, both of which would be beneficial for women’s
health services and public mental health.
Keywords: mothers; mood; anxiety; mental health; women’s health; postnatal depression; postpar-
tum; polyphenols; diet
1. Introduction
The beneficial effects of polyphenols on health ([1–3] for reviews) and cognition ([4–8]
for reviews) have been well reported within the literature. Recent investigations have
focused on the impact of polyphenols on mood and have discovered advantageous effects
in healthy child [9], adolescent [10] and adult [9,11] populations after polyphenol-rich
food interventions. Such findings suggest that consuming foods high in flavonoids may
improve or maintain positive mood in healthy populations. This also holds promise for
populations with symptoms of low mood, or for those ‘at risk’ of developing mental health
conditions such as postnatal depression (PND) or anxiety, both of which are rising public
health concerns. Dietary intervention, such as flavonoids, may offer natural protection
from symptom onset or lessen symptom severity. The current exploratory study aimed to
assess mood, depression, anxiety and perceived quality of life before and after a 2-week
high flavonoid dietary intervention in a sample of new mothers who had an infant under
1 year old.
PND is defined as an episode of major depressive disorder (MDD) commonly experi-
enced by parents following the birth of their baby and affects approximately 1 in 10 new
parents [12]. PND can affect both parents; around 8–10% of new fathers have been reported
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to develop PND in the first year following their baby’s birth [13] with yearly prevalence in
mothers estimated at 10–15% [14]. Concerningly, it has been indicated that prevalence in
mothers may be as high as 60% worldwide [15]. These statistics indicate PND as a serious
clinical issue for postnatal healthcare services [16] and investigation into early interventions
to prevent PND onset or lessen severity is warranted.
PND is distinct from postpartum blues (PPB; ‘baby blues’); the latter is a state expe-
rienced by 50–80% of mothers in the first few days following childbirth which includes
symptoms such as crying, decreased appetite, mood swings, worrying and exhaustion. PPB
is generally considered a ‘normal’ experience for new mothers by healthcare professionals;
indeed, symptoms usually resolve within 2 weeks of birth and do not appear to negatively
impact long-term maternal function [17]. PND, however, is classified as an episode of MDD
that lasts longer than 2 weeks, generally occurs within 6 months of birth and negatively
affects daily functioning [18,19]. Symptoms of PND are similar to MDD and include low
mood, fatigue, feelings of guilt, inability to concentrate, mood swings, difficulty bonding
with one’s baby, withdrawal from family and friends, irrational anger, intense irritability
and thoughts of harming oneself or one’s baby [19], and research has shown that mothers
with PND experience more cognitive, behavioural and interpersonal difficulties, including
lower mood, energy and concentration than mothers without PND [20]. Such symptoms
can significantly affect mothers’ perceived quality of life and ability to cope with daily
living; in severe cases it can lead to psychosis or suicide, the latter being the most common
form of maternal death in the postnatal period [21]. It is therefore imperative that persistent
low mood in populations at risk of developing a depressive disorder is addressed, and a
range of preventative treatments are investigated to reduce mental health disturbances in
new mothers.
PND has been the focus of postnatal mental health research, most likely due to its
prevalence and similarities with MDD in terms of diagnosis and treatment. It is, however,
critical to assess other postnatal affective states or psychological disorders, such as anxiety,
so that these can be distinguished and treated separately [22]. The current study will
assess current mood, anxiety and quality of life outcomes in addition to a measure of
depression so that the impact of dietary intervention can be assessed across a wider range
of mood states and lifestyle factors. This is important so that other mood changes can be
captured independently of PND, which may aid treatment specificity for other disorders.
Current treatments for mood disturbances in the postnatal period (i.e., PND, anxiety)
include psychological therapy and antidepressants, however both have varying success
rates [23]. There is a pressing need to investigate natural alternatives to medication which
are cost-effective, easy to access and easy to self-implement.
Flavonoids are naturally occurring plant compounds, commonly found in berries,
citrus fruits, vegetables, cocoa, red wine, tea and coffee. Research has found that long-
term consumption of flavonoids may support mental health and well-being. For instance,
epidemiological research has found that consistent consumption of food and drink items
high in flavonoids, such as fruits, vegetables and tea are predictive of reduced depression
risk in later life [24]. In a sample of adults living in southern Italy, Godos et al. [25] found
that higher dietary intake of foods abundant in specific flavonoid subclasses (phenolic
acid, anthocyanins and flavanones) was significantly related to lower depressive symp-
toms. Symptoms reduced in a dose-response manner to higher levels of anthocyanins and
flavanones, suggesting that high levels of particular flavonoid subclasses may underlie
observed mood effects. A recent review [26] identified 29 studies where symptoms of
depression in young adult populations were alleviated following polyphenol intervention,
indicating a clear link between high consumption levels and improved mood outcomes.
It is interesting to note that there are a number of studies showing that dietary sources of
anthocyanins or flavanones have beneficial effects on chronic mood [10,11]. For example,
Pase et al. [11] reported significantly enhanced feelings of calmness and contentedness in
middle-aged adults (40–65 years) following a 30-day daily cocoa intervention. Across a
similar timeframe, positive mood effects were also observed in an adolescent population
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(12–17 years), with participants reporting significantly lower depressive symptoms at the
end of a 4-week daily wild blueberry intervention [10]. Improvements in quality of life
have also been observed in a depressed sample (50–55 years) following a 12-week daily
soy and resveratrol intervention [27]. Such results suggest that daily supplementation with
flavonoid-rich foods or supplements may have a positive impact on mood, quality of life
or depressive symptoms in healthy and depressed individuals.
Mechanistically, these findings are supported by animal research that suggests that
flavonoids may alleviate symptoms of anxiety via neuronal signaling pathways ([28] for
review). Allam et al. [29] conducted a study in rats where oxidative stress (OS) was chemi-
cally induced, and high anxiety-like behaviours were subsequently observed. Following a
3-week daily grape powder intervention (15 g/L), OS grape-fed rats showed significantly
fewer anxiety-like behaviours compared to OS control-fed rats, at a level similar to healthy
(non-OS-induced) control and grape-fed rats. This implies that an absence of OS may
be associated with low levels of anxiety, or that OS results in higher levels of anxiety.
Positive changes in extracellular signal-regulated kinase 1/2 (ERK-1/2), cAMP-response
element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) were also
observed in OS grape-fed rats, to a similar degree as control-fed and grape-fed rats. Such
activation of signaling pathways was not observed in OS control-fed rats. These findings
imply that flavonoids may be able to reduce anxiety symptom intensity by reducing OS,
potentially through neuronal signaling mechanisms. Similar ameliorations in chronic
stress-induced behaviours have been observed in rodents post-kaempferol intervention
(the major flavonoid compound in broccoli, tea and strawberries; [30]), believed to be
modulated by reductions in OS, inhibition of inflammatory cytokines and up-regulation of
AKT/B-catenin cascade. Hesperidin, a flavonoid found in citrus fruits, has been reported
to reduce depressive-like behaviours in mice through kappa-opiod (involved in dopamine
transmission; [31]) or serotonergic pathways [32]. Such findings hold implications for
the potential for flavonoids to exert effects on mood, specifically anxiety, using similar
neuronal mechanisms as cognitive change [33–36]. There are a number of other mecha-
nisms by which flavonoids may exert mood effects such as changes in cerebral blood flow,
transmission of GABA or monoamine oxidase inhibition.
In light of the positive indications for mood and well-being after consumption of
flavonoid-rich foods (particularly in domains associated with low mood or depression),
exploring this relationship in a human sample at risk of mood disorders, such as new
mothers, merits investigation. Therefore, this exploratory study aimed to investigate
whether the addition of high flavonoid foods in the diet across a 2-week period can
impact maternal mental health, specifically mood and perceived quality of life in the
0–12 month postnatal period, relative to a control group. It was hypothesised that mothers
in the flavonoid diet group may report reduced symptoms of depression and anxiety, and
increased positive mood and perceived quality of life after the 2-week intervention.
2. Materials and Methods
This research project was reviewed and given a favourable ethical opinion for conduct
by the University of Reading School of Psychology and Clinical Language Sciences Ethics
Committee (2020-075-KB).
2.1. Sample
Forty-one mothers were recruited via mother and baby pages on social media within
a 6-week period, of which 38 mothers completed demographic information. The sample
was 84% white; 11% Asian or Asian British; 3% Black/African/Caribbean/Black British;
3% Latino or Hispanic, educated (49% further; 38% higher) with most women in a domestic
partnership (82%). Annual household income varied across the sample; 32% of households
reported above average income (>£41,000), 37% fell in line with the current UK average
(£31–40,000; UK average = £37,108 [37]) and 26% reported below average income (<£30,000).
This was unsurprising as it was expected that a household with a new baby may have reduced
working hours; indeed 58% of women were on maternity leave with only 34% in employment
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at the time of the study (full time = 8%; part time = 13%; self-employed = 13%). No women
reported unemployment and 8% of women were students.
All women had a baby under the age of 12 months, with baby’s age ranging from 5 to
48 weeks. For 28 women this was their first child, whereas 9 women indicated that they
also had other children (number of other children mode = 1, range 1–3). The majority of
women (82%) stated that they had childcare support (e.g., nearby family) with only 18%
reporting no support outside of the family home.
Eleven women had a psychological diagnosis: 5 with anxiety, 3 with PND, 2 with
anxiety and depression and 1 with anxiety and eating disorder. Of these 11 women, 7 were
on antidepressant selective serotonin reuptake inhibitor (SSRI) medication. The remaining
4 women with diagnoses were not on medication. It was important to include individuals
with psychological diagnoses (28.95%) in the study as this was thought to reflect similar
proportions in the postnatal population at the time (29.8% anxiety and/or depression
diagnoses, Spring/Summer 2020 [38]). Nine women reported physical health diagnoses:
5 with asthma, 1 with diabetes, 1 with Crohns disease, 1 with Hodgkin lymphoma and 1
with asthma and arthritis. Similarly, individuals with physical diagnoses were included to
reflect real life prevalence.
An a-priori power calculation using GPower 3.1 [39] revealed that 44 participants were
required to achieve a power of 0.8 using an effect size (Cohen’s d) of 0.22 (F(1,42) = 4.07).
This effect size was used based on prior research that has shown significant flavonoid-
related mood effects [9,10]. A post-hoc power analysis confirmed that a sufficient power
of 0.78 was achieved with the current sample size of 41 (F(1,39) = 4.09). There were no
significant differences in demographic variables between the flavonoid and control group
(see Table 1).
Table 1. Demographic data for mothers and babies in flavonoid and control groups.
Measure
All Participants Flavonoid Group (n = 19) Control Group (n = 19) Between
Groups p
Value aMean (SD) Mean (SD) Range Mean (SD) Range
Age of mother (years) 29.21 (5.67) 29.58 (5.69) 20–41 28.84 (5.78) 20–41 0.70
Sleep of mother (h/night) 6.03 (1.15) 6.00 (1.25) 3–8 6.05 (1.08) 4–8 0.89
PHQ-8 symptomology 1 16:3:1:1 7:2:1:0 - 9:1:0:1 - 0.47
State anxiety symptomology 2 11:22 4:11 - 7:11 - 0.46
Age of baby (weeks) 21.5 (8.35) 23.11 (7.76) 5–35 19.89 (8.81) 5–43 0.24
Sex of baby (female:male) 20:18 10:9 - 10:9 - 1.00
Term of baby (very
early:early:full:late) 3 2:12:18:6 0:6:9:4 - 2:6:9:2 - 0.45
Feeding method 4
0–6 months 18:3:10:7 8:3:6:2 - 10:0:4:5 - 0.18
6–12 months 5 4:8:6:6 2:6:4:2 - 2:2:2:4 - 0.35
Complications (yes:no)
Pregnancy 8:30 6:13 - 2:17 - 0.11
Birth 7:31 3:16 - 4:15 - 0.67
Breastfeeding 12:16 7:12 - 5:14 - 0.49
Habitual diet (items/day)
Flavonoid 6 4.05 (2.52) 4.56 (2.44) 1–10 3.64 (2.59) 0–12 0.30
Junk food 1.85 (1.84) 1.61 (1.18) 0–5 2.09 (2.34) 0–11 0.43
1 Mild (score of 5): moderate (score of 10): moderately severe (score of 15): severe (score of 20+); 2 Below cut-off: above cut-off. A cut-off
of 36 was used as it has been deemed predictive of disordered anxiety in a postnatal population [40]; 3 Very early term = born between
32–36 weeks; Early term = born between 37–38 weeks; Full term = born between 39–40 weeks; Late term = born at 41 weeks+; 4 Frequency
of babies breastfeeding: formula feeding: combination feeding: prefer not to say; 5 Flavonoid n = 14, Control n = 10; 6 Mean flavonoid items
per day; flavonoid n = 15, Control n =18. a Post-hoc achieved power for between group baseline comparisons using an effect size of d = 0.3
(small) was low (0.23); t (36) = 1.69.
2.2. Design
Participants were randomly assigned (using a random number generator) to either
a ‘flavonoid’ group (n = 21) or a ‘control’ group (n = 20) by the researcher. The flavonoid
group were instructed to add at least one high flavonoid food item from a specified list to
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their daily diet for 2 weeks. The control group were not given instructions and so made no
changes to their current diet. Mood, anxiety, depression and quality of life measures were
recorded at baseline and at the end of the 2-week intervention in both groups.
2.3. Intervention
The flavonoid group were encouraged to continue eating as normal and to add at
least 1 high flavonoid food item per day (from a designated list) to their current diet.
The list of high flavonoid food items included ‘berry fruits (~120 g) e.g., blueberries,
raspberries, strawberries, blackberries, blackcurrants, mixed berries’, ‘2 large squares of
(min. 70% cocoa) dark chocolate’, ‘4–5 cups of black/green tea or caffeinated/decaffeinated
coffee’, ‘1 large glass of red wine (250 mL)’, ‘1 portion of leafy green vegetables such as
spinach or cabbage (~70 g)’ and ‘1 glass (250 mL) of fresh orange or grapefruit juice (not
from concentrate)’. These items were chosen from the USDA Database for the Flavonoid
Content of Selected Foods [41] for their high flavonoid content, likeability, accessibility and
affordability in a sample that were likely to be time- and money-limited. Portion guidelines
were decided based on average adult consumption of these foods in one sitting (or per
day for tea and coffee). These items were also selected to cover a breadth of flavonoid
subclasses in foods that are realistically consumed in the average diet. It was important to
use food items and portion sizes that were agreeable, achievable and were indicative of
real-life consumption.
Participants in the flavonoid group completed a food log every day of the 2-week
intervention to record the flavonoid food item(s) added to their diet. According to food
logs, participants consumed an average of 15.45 (SD = 4.33) high flavonoid items over the
14-day intervention period and missed, on average, 2 out of 14 days (SD = 2.10), which
suggests good overall compliance (86%). Within the high flavonoid diet group, coffee was
the most consumed food, followed by berry fruits. A full breakdown of high flavonoid
food additions in the high flavonoid group can be seen in Table 2.
Table 2. Breakdown of the number of high flavonoid foods added to the diet per person across the
2-week intervention in the flavonoid diet group (n = 20). Units represent the average (SEM) number
of occasions an item was consumed per person across 2 weeks.
High Flavonoid Food Item Added to the Diet Mean (SD) Number of Occasions Item WasAdded over 2-Week Period (Per Person)
Coffee (4–5 cups) 3.65 (3.86)
Berry fruits (~120 g) 3.45 (2.61)
Tea (4–5 cups) 3.40 (4.17)
Orange juice (250 mL) 1.75 (2.22)
Leafy green vegetables (~70 g) 1.10 (1.52)
Dark chocolate (2 large squares) 0.65 (1.09)
Red wine (250 mL) 0.55 (0.89)
Grapefruit juice (250 mL) 0.40 (0.88)
Participants in the control group did not receive any instructions regarding changes
to their diet and so continued consuming their typical diet. This group did not complete
flavonoid food logs as they were not required to add items to their diet. These participants
were aware that the study was investigating diet and mental health in new mothers and at
the end of baseline were told they would be invited to complete questionnaires again in
2-weeks’ time.
Participant blinding of each group was achieved as the study was advertised as an
investigation into “diet and mothers’ mental health”. The groups were told that some
participants may be asked to include additional common food items to their diet over a
2-week period, meaning they were aware that there were two separate groups but did
not know the exact dietary focus of the intervention. The recruiting researcher was not
blind to participant group membership due to them needing to know which information
to send throughout the course of the study (e.g., high flavonoid diet sheets, food logs).
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This researcher only ever engaged with participants via email and the wording in these
emails was standardised for consistency. Data analysis was completed fully blinded, by a
different researcher.
2.4. Measures
All measures were administered online using Microsoft Forms. Due to the number of
questionnaire items across the study, measures were distributed across two online links
and were labelled ‘Part 1’ and ‘Part 2’. Participants were instructed to complete these
parts consecutively.
2.4.1. Habitual Flavonoid Consumption
A 35-item Food Frequency Questionnaire (FFQ) was administered at baseline to record
individuals’ habitual flavonoid and junk food intake (see Table 1). Habitual flavonoid intake
was derived from 22 items taken from the European Prospective Investigation of Cancer
Food Frequency Questionnaire (EPIC-FFQ [42]): leafy green vegetable soups, tea (black,
green, fruit, white, other), coffee, cocoa, red wine, beer/lager/cider, pure fruit juice (100%),
apples, oranges/satsumas/mandarins, grapefruit, strawberries/raspberries/blueberries,
dried fruit e.g., raisins, cranberries, blueberries, broccoli/spring greens/kale, leeks, onions
and tomatoes. Participants rated how often they consumed each item on a 7-point Likert
scale: (1) Never or less than once/month, (2) 1–3 times per month, (3) 1–2 times per week,
(4) 3–5 times per week, (5) Once per day, (6) 2–3 times a day, (7) 4+ times a day. Each
participant response was converted to average number of flavonoid food items per day for
each participant. Junk food items (not analysed) were added as a ‘filler’, so participants
believed they were answering a general diet questionnaire rather than one specific to
flavonoid intake.
2.4.2. Mood
The Positive and Negative Affect Schedule (PANAS-NOW; [43]) was used to assess
participants’ current mood (full details in [9]). The PANAS has shown to be sensitive to
flavonoid effects previously [9] and is a quick and reliable measure. Scores of positive
affect (PA) and negative affect (NA) were calculated (range 20–80), where a higher score
was indicative of higher PA or NA.
2.4.3. Anxiety
Participants completed the State-Trait Anxiety Inventory (STAI; [44]) which consisted
of 40 items. Twenty items of the STAI related to ‘state’ anxiety—the presence and severity
of current anxiety symptoms. All items were rated on a 4-point Likert scale. On ‘state’
anxiety items, responses were ‘Not at all; Somewhat; Moderately so; Very much so’ and
were indicative of how participants felt ‘at this moment’. On ‘trait’ anxiety items, responses
applied to the frequency of feelings ‘in general’: ‘Almost never; Sometimes; Often; Almost
always’. Items were appropriately reverse coded and summed to create ‘state’ anxiety (SA)
and ‘trait’ anxiety (TA) scores (range 20–80; [45]). Higher SA and TA scores were indicative
of higher state and trait anxiety, respectively.
2.4.4. Depression
The Patient Health Questionnaire 8 (PHQ-8; [46]) was administered as a measure
of depressive symptoms. The PHQ-8 has been found to be a reliable measure of current
depression in the general population [47] and is appropriate for use in a non-clinical sample.
The questionnaire includes 8 items that relate to the Diagnostic and Statistical Manual
(DSM-IV) criteria for depression, excluding suicidal ideation. Participants rated how often
they were bothered by each of the 8 items during the past 2 weeks on 4-point Likert scales.
Responses were logged from ‘0—Not at all’ to ‘3—Nearly every day’. An overall score was
derived by summing the responses from the 8 items (range 0–24). Cut-off scores were used
to categorise the severity of depression symptoms: 5 = mild depression, 10 = moderate
depression, 15 = moderately severe depression and 20+ = severe depression [46].
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2.4.5. Perceived Quality of Life
The World Health Organization Quality of Life (WHOQOL-BREF; [48]) questionnaire
was also used in the current study. The WHOQOL-BREF is an abbreviated version of
the WHOQOL-100, a well-validated, international questionnaire that allows detailed
assessment of perceived quality of life. The WHOQOL-100 was deemed too lengthy
and time consuming for use in the current study. The WHOQOL-BREF has been deemed
suitable for investigating changes in quality of life across intervention studies lasting a
minimum of 2 weeks making it appropriate for use in the current study.
The WHOQOL-BREF contained one item from each of the 24 facets of the WHOQOL-
100 that relate to aspects of perceived quality of life including energy, fatigue, sleep, rest,
bodily image, self-esteem, personal relationships, social support, financial resources, health
and social care and home environment, and two additional items from overall quality of life
and general health facets. Questionnaire items were rated using 5-point Likert scales where
‘1’ represents ‘Very poor; Very dissatisfied; Not at all; Never’ and ‘5’ represents ‘Very good;
Very satisfied; An extreme amount; Extremely; Completely; Always’. Items were summed
and standardised appropriately into four domains: Physical Health, Psychological, Social
Relationships and Environment. A higher score was indicative of a higher perception of
aptitude or quality in each domain.
2.5. Procedure
Participants completed assessments of mood and quality of life on two separate
occasions, at baseline (day 0) and 2 weeks later. At baseline, participants completed
a demographics questionnaire about themselves and their baby, which was labelled as
optional due to the personal nature of some questions. Several risk factors for PND have
previously been identified including pregnancy complications, prematurity of baby and
maternal age (adolescents and women over 35 years having higher risk [49]). Other risk
factors include being single [50] and having multiple children [51]. It was important that
these measures were captured to characterise the sample, so mothers were asked their age,
marital status, number of other children, pregnancy complications and their baby’s term at
birth. Other demographic questions included gender, ethnicity, education, employment,
household income, psychological and physical health diagnoses, medication, average
sleep per night (hours), nearby childcare support and birth or breastfeeding complications.
Participants also answered various questions about their baby: age, sex and feeding method
(breast milk, formula or combination) at 6 and 12 months (see ‘2.1 Sample’ and Table 1).
Participants answered questionnaires in the following order: PANAS-NOW, FFQ,
PHQ-8, WHOQOL-BREF and STAI. Completion of the baseline session indicated the
start of the 2-week intervention for that participant. At the end of the baseline session,
participants in the flavonoid condition were presented with instructions on consuming
additional food items for 2 weeks. Instructions also contained a 14-day food log where
participants were required to fill in which additional food item(s) from the list they had
added to their daily diets. If participants missed a day, they were encouraged to record
the day as ‘missed’ and continue with the diet as normal the next day. Participants in the
flavonoid condition were emailed on day 5 of the intervention to check progress and to
remind them to complete food logs.
Participants who were assigned to the control condition did not receive instructions
nor a 14-day food log. Upon completing the baseline session, control participants were
told they had completed the first half of the study and would be invited to take part in the
second part of the study in 2 weeks’ time.
Participants in both conditions were emailed on day 10 of their respective intervention
periods with the link to the second part of the study. They were encouraged to complete
this when convenient on day 14. Follow-up email reminders were sent on day 14 and on
day 16 for those who had not yet completed the second part by the end of day 14.
The study was conducted across a 6-week period between July and August 2020, after
which funding for the project ceased, marking the end of the trial. Participants completed
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staggered baseline sessions across weeks 0–4 with intervention commencing immediately
for 2 weeks. Participants were to cease consumption of additional food items (if in the
flavonoid group) and complete follow-up questionnaires 2 weeks after their individual
baseline session. Week 4 was the final week for recruitment of new participants to allow all
participants to complete the 2-week trial in the 6-week period.
2.6. Statistical Analyses
Some missing data were evident due to participants only completing Part 1 or moving
on to Part 2 without correct submission of Part 1 questionnaire responses. At baseline,
2 data points were missing from the PANAS (flavonoid (F) = 1; control (C) = 1), 7 from the
STAI (F = 5; C = 2), 7 from the PHQ-8 (F = 5; C = 2) and 7 from the WHOQOL-BREF (F = 5;
C = 2). At 2 weeks, 5 were missing from the PANAS (F = 3; C = 2), 4 from the STAI (F = 2;
C = 2), 5 from the PHQ-8 (F = 3; C = 2) and 5 from the WHOQOL-BREF (F = 3; C = 2).
Data were analysed using SPSS Statistics version 24.
Independent samples t-tests and chi-square (where appropriate) were performed to
assess whether there were significant group differences for demographic and baseline data.
Outcome data from the PANAS-NOW (PA, NA), STAI (State, Trait), PHQ-8 and
WHOQOL-BREF (Physical, Psychological, Social, Environmental) were analysed using
separate linear mixed models (LMM) where Group (Flavonoid, Control) and Time (Baseline,
2 weeks) were fixed factors. An unstructured covariance matrix was used to model the
repeat effects of Time. Participant was implemented as a random factor. Significant
interactions were explored using Bonferroni-corrected pairwise comparisons between and
within groups.
3. Results
Demographic and dependent variable data can be observed in Tables 1 and 3, re-
spectively, where no significant baseline differences occurred between flavonoid and
control groups.




2 Weeks Change from Baseline Interaction
p Value
Measure Flavonoid Control Flavonoid Control Flavonoid Control
PANAS-NOW (n = 19) (n = 19) (n = 17) (n = 18)
PA 29.53 (6.88) 26.95 (8.42) 0.27 30.65 (4.82) 28.50 (6.42) −0.78 (11.06) −0.44 (6.90) 0.71
NA 19.58 (6.43) 20.11 (8.69) 0.89 17.39 (7.29) 18.39 (7.52) −2.56 (4.24) −2.61 (9.20) 0.59
STAI (n = 15) (n = 18) (n = 18) (n = 18)
State anxiety 40.27 (9.66) 38.33 (10.59) 0.84 36.56 (5.86) 39.06 (9.39) −4.21 (5.49) 0.82 (5.43) 0.02 *
Trait anxiety 44.53 (7.61) 41.94 (7.57) 0.29 40.50 (7.65) 38.72 (7.97) −3.42 (2.59) −3.00 (5.32) 0.72
PHQ-8 (n = 15) (n = 18) (n = 17) (n = 18)6.47 (4.64) 5.56 (5.19) 0.60 5.65 (3.35) 5.06 (4.33) −0.62 (3.50) −0.12 (3.64) 0.80
WHOQOL-BREF (n = 15) (n = 18) (n = 17) (n = 18)
Physical 40.13 (9.38) 44.89 (8.48) 0.14 47.06 (8.79) 43.94 (6.93) 5.62 (8.31) −0.29 (6.01) 0.01 *
Psychological 49.73 (11.20) 55.00 (9.24) 0.15 54.53 (11.47) 56.44 (9.41) 4.23 (8.24) 1.18 (7.58) 0.24
Social 55.27(18.77) 55.72 (16.98) 0.94 61.94 (13.74) 61.28 (17.75) 7.15 (13.96) 5.53 (18.04) 0.81
Environment 66.73 (11.57) 66.44 (14.43) 0.95 66.35 (9.47) 66.11 (9.94) 1.00 (8.84) −1.06 (14.65) 0.92
PANAS-NOW: Positive and Negative Affect Schedule; PA: positive affect; NA: negative affect; STAI: State-Trait Anxiety Inventory; PHQ-8:
Patient Health Questionnaire 8; WHOQOL-BREF: World Health Organization Quality of Life (abbreviated version). * represents significance
(p < 0.05) following Bonferonni adjustments.
Mothers in the high flavonoid condition reported significantly lower state anxiety at
the end of the 2-week intervention compared to baseline (p < 0.01; Figure 1a). This effect
was not observed in the control group (p = 0.58). No significant main effects of Condition
or Time were observed.




Figure 1. (a) Mean (SEM) state anxiety was significantly lower for mothers at 2 weeks compared to baseline (F(1,32) = 5.93, 
p = 0.02); (b) Mothers in the flavonoid group rated mean (SEM) quality of their physical health as significantly better at the 
end of the intervention compared to baseline (p < 0.01). * p = 0.01. 
There were four significant main effects of Time on Trait anxiety (F(1,33.15) = 20.07, 
p < 0.01), Quality of Physical Health (F(1,33.39) = 5.19, p = 0.03), Quality of Psychological 
Health (F(1,33.01) = 4.31, p = 0.046) and Quality of Social Relationships (F(1,35.51) = 5.11, p 
= 0.03). Trait anxiety was significantly lower for all participants post-intervention com-
pared to baseline (mean change = −3.31). Whereas perceived Quality of Physical Health 
was rated significantly higher at the end of the intervention compared to baseline, regard-
less of group (mean change = 2.78), as was perceived Quality of Psychological Health 
(mean change = 2.82) and Quality of Social Relationships (mean change = 6.25). Across 
time, reductions in NA approached significance (mean change = −1.91; F(1,36.71) = 3.94, p 
= 0.055). 
No significant effects were observed in PA, perceived Quality of Environment or 
PHQ-8 measures. 
4. Discussion 
The current exploratory study recruited a sample of new mothers who had a baby 
under 1 year old to measure current mood, anxiety, depression and perceived quality of 
life, before and 2 weeks after a daily dietary flavonoid intervention as part of a random-
ised, controlled trial. In mothers who incorporated additional high flavonoid foods into 
their diet, levels of state anxiety significantly reduced across time, suggesting that regular 
consumption of flavonoids may have alleviated feelings of anxiousness in transitory emo-
tional states. Flavonoid-supplemented mothers also reported a significant improvement 
in perceived quality of physical health, a domain that incorporates measures of energy, 
fatigue, activities of daily living and dependence on medication. 
Mothers in the control group who were instructed to continue with their normal diet 
did not show any change in anxiety scores. This suggests that regular intake of flavonoids 
from typical dietary sources may alleviate feelings of state-dependent anxiety in new 
mothers, and would be a relatively accessible, cost-effective and manageable change for 
new mothers and family units to adopt during a period in which they may be under psy-
chological, physical and financial strain. Indeed, 67% of mothers scored above the clinical 
cut-off for anxiety in a postnatal population [40] (Table 1) and 64% of mothers displayed 
depression symptomology as stipulated by the PHQ-8 [46] (Table 1), indicating the sam-
ple were experiencing moderate-high levels of anxiety and/or depression at day 0 (base-
line). Only 12 women had no symptoms of depression as stipulated by the PHQ-8, a con-
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end of the intervention co pared to baseline (p < 0.01). * p = 0.01.
Intervention-related effects were also observed in the Quality of Physical Health do-
main where participants in the high flavonoid condition experienced significantly higher
perceived quality of physical health at the end of the 2-week intervention compared to base-
line (p < 0.01). This pattern did not occur for control participants (p = 0.75; F(1,33.39) = 7.32,
p = 0.01; Figure 1b).
There were four significant main effects of Time on Trait anxiety (F(1,33.15) = 20.07,
p < 0.01), Quality of Physical Health (F(1,33.39) = 5.19, p = 0.03), Quality of Psychological
Health (F(1,33.01) = 4.31, p = 0.046) and Quality of Social Relationships (F(1,35.51) = 5.11,
p = 0.03). Trait anxiety was significantly lower for all participants post-intervention com-
pared to baseline (mean change = −3.31). Whereas perceived Quality of Physical Health
was rated significantly higher at the end of the intervention compared to baseline, regard-
less of group (mean change = 2.78), as was perceived Quality of Psychological Health
(mean change = 2.82) and Quality of Social Relationships (mean change = 6.25). Across
time, reductions in NA approached significance (mean change = −1.91; F(1,36.71) = 3.94,
p = 0.055).
No significant effects were observed in PA, perceived Quality of Environment or
PHQ-8 measures.
4. Discussion
Th curr nt explor tory study re ruited a sample of new mothers who ad a baby
under 1 year ld to measure current mood, anxi ty, depression and perceived quality f
life, before and 2 weeks after a daily dietary flavonoid intervention as part of a randomised,
controlled trial. In mothers who incorporated additional high flavonoid foods into their
diet, levels of state anxiety significantly reduced across time, suggesting that regular con-
sumption of flavonoids may have alleviated feelings of anxiousness in transitory emotional
states. Flavonoid-supplemented mothers also reported a significant improvement in per-
ceived quality of physical health, a domain that incorporates measures of energy, fatigue,
activities of daily living and dependence on medication.
Mothers in the control group who were instructed to continue with their normal
diet did not show any change in anxiety scores. This suggests that regular intake of
flavonoids from typical dietary sources may alleviate feelings of state-dependent anxiety
in new mothers, and would be a relatively accessible, cost-effective and manageable
change for new mothers and family units to adopt during a period in which they may
be under psychological, physical and financial strain. Indeed, 67% of mothers scored
above the clinical cut-off for anxiety in a postnatal population [40] (Table 1) and 64% of
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mothers displayed depression symptomology as stipulated by the PHQ-8 [46] (Table 1),
indicating the sample were experiencing moderate-high levels of anxiety and/or depression
at day 0 (baseline). Only 12 women had no symptoms of depression as stipulated by the
PHQ-8, a contrasting difference to the 29 women reporting no psychological diagnoses.
These proportions interestingly align with research that suggests rates of PND are higher
than initially acknowledged, potentially as high as 60% [15]. In the current sample at
least, depressive symptoms do appear to be common amongst a mostly diagnosis-free
group. This supports the notion that mothers in the 0–12-month postnatal period may be
psychologically ‘at risk’ and may experience symptoms of psychological disorders without
full recognition, support, diagnosis or treatment. Further, this highlights potential for
further research into the barriers of PND diagnosis and subsequent treatment.
It must be highlighted that the findings from this study are to be considered in the
context of the COVID-19 pandemic. Research conducted during the first UK national
lockdown in 2020 [52] found that state anxiety (assessed using the STAI state scale (STAI-S))
amongst new mothers was high with 61% of women in the 0–12 week postnatal period
reporting a score of 40 or above, signifying clinically relevant anxiety [38]. Additionally,
pandemic levels of anxiety were significantly higher than pre-pandemic levels of anxiety,
assessed by comparison to a study using matched methods and recruiting a postnatal
population of similar characteristics [53]. As the current study was conducted in the
interim between the UK’s first and second national lockdowns, it is likely that anxiety
remained high, and this may have contributed to higher-than-average state anxiety scores.
Replication of this study in non-pandemic circumstances is therefore warranted.
It is important to note that the STAI used to measure anxiety did not include hallmark
clinical (DSM-V) symptoms of generalised anxiety disorder (GAD; [19]) such as irritability,
fatigue or restlessness. Results should not, therefore, be interpreted as a reduction in GAD
symptoms specifically, but a reduction in problematic thoughts and feelings that may make
an individual feel anxious in any one given state. Early motherhood can be viewed as
a series of new situations or ‘states’ which may be prone to anxiety and so a measure of
thoughts and feelings without physical symptoms is perhaps a more informative measure
to use in a postpartum population. The STAI was used in the current study to capture
participants’ state anxiety in this vulnerable period and has been recognised as a valid
screening tool for depression and anxiety disorders in the postnatal period [40]. However,
research has found that feelings of anxiety in new mothers are not necessarily generalised,
as in non-childbearing populations with GAD, but are more maternal- and infant-focused,
and include worries about maternal competency, mother-infant attachment, infant safety,
practical infant care and psychosocial adjustment to motherhood [54]. It is important that
future research acknowledges the distinction between GAD and postpartum anxiety and
uses appropriate additional measures to capture anxiety in a postpartum population, such
as the Postpartum Specific Anxiety Scale [54] alongside measures of state anxiety.
Presently, the flavonoid intervention was also associated with significantly higher per-
ceived quality of life in the domain of Physical Health, whilst no change was observed for
the control group. This measure encompasses seven facets including activities of daily living,
dependence on medicinal substances and medical aids, energy and fatigue, mobility, pain and
discomfort, sleep and rest and work capacity [48]. Depletion in these facets is common in new
mothers, suggesting that the physical health domain may have a higher capacity for change.
Currently, there are no WHOQOL normative data for non-patient, parent populations, so it is
unclear if the change in physical quality of life observed in this study is clinically meaningful.
Previous healthy young adult data (n = 240, mean age = 22.9 years (SD = 3), 47% male) estab-
lished a standardised physical health mean score of 78.83 (SD = 13.09) [48], which is noticeably
higher than standardised baseline scores of flavonoid (mean = 40.13, SD = 9.38) and control
(mean = 44.89, SD = 8.48) participants in the current study (mean age = 29.21, SD = 5.67).
Interestingly, physical health data in the current sample are closer to the standardised norms
of caregivers of relatives with psychiatric illness (mean = 53.43 (SD = 14.2), n = 266, mean
age = 37.3 years (SD = 11.3), 52.6% male) [55] and patients with type 2 diabetes (mean = 48.1
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(SD = 20.4), n = 344, mean age = 40.54, SD = 15.21, 57.3% male) [56], suggesting that an
all-female, new mother sample may have lower than average norms for quality of life, as
indicated by the current results. Indeed, psychological, social and environmental domains
also appear to be lower than published norm data [48,55,56]. Further studies recruiting a
larger N should aim to establish normative data for this population. Forthcoming research
should investigate what may be driving the improvement in physical quality of life, for
example which physical factor in particular may be boosted by flavonoid consumption. The
other measures of quality of life (social, psychological or environment) were not affected
by the intervention. It is perhaps ambitious to expect a two-week dietary intervention to
improve mothers’ perceptions of their social connections and overall living environment, but
it is more plausible that changes in psychological quality of life could be detected. Given the
observed benefits to anxiety, but absence of effects for depression, it appears that changes in
psychological state are subtle, and the psychological quality of life measure is likely unsuitable
for detecting these changes. It may be more sensitive to long terms changes such as several
months or more.
The absence of differences between the flavonoid and control group, or indeed any
changes over time for the measures of depression (PHQ-8) and positive affect implies that
a 2-week dietary flavonoid intervention may not be sensitive enough to impact depressive
symptoms and related affective components in a postnatal population. This is contrary to
findings by Fisk et al. [10] who observed a significant reduction in depressive symptoms
(using the Mood and Feelings Questionnaire) in adolescents following a 4-week WBB
regimen. It is possible that two weeks is not long enough to detect changes in depressive
symptoms. Furthermore, considering the current population, the PHQ-8 may not have
been specific enough to assess symptoms of PND; PHQ-8 items are more focused on
symptoms of MDD. Future investigations should consider using validated PND-specific
scales (such as the Edinburgh Postnatal Depression Scale) to ensure that the full range of
possible PND symptoms are measured. Of relevance here is that only three participants
had a PND diagnosis in the current study. The absence of specific depression-related
effects may be due to most participants who had depressive symptoms fitting in the ‘mild’
depression category at baseline (42%). Much lower prevalence was seen in the higher
depression categories of ‘moderate’ (8%), ‘moderately severe’ (3%) and ‘severe’ (3%) where
the potential for improvement in symptoms may be higher.
Interestingly, in addition to state anxiety reductions in the flavonoid group, significant
reductions in trait anxiety and NA were observed over time for both groups, which may
have been a by-product of taking part in a study which drew attention to individuals’ mood
states. Awareness of mood can be therapeutic in itself [57] and, in retrospect, it would
have been interesting to ask mothers how they labelled and interpreted their responses to
baseline mood questionnaires and whether they explored any mood materials or self-help
literature after taking part in the initial baseline session. Another possible methodological
consideration is that the very act of consciously logging intake of a high flavonoid food
could positively influence mood outcomes, by potentially highlighting a positive dietary
behaviour. The control group were not asked to make any recordings of their diet during
the 2-week period, and therefore this is an unavoidable confound within the design. The
alternative was to ask the control group to report dietary intake during the 2-week period,
however, this brings other limitations such as changes in dietary behaviour and potentially
reduced compliance, which reduces the validity of a control group. Further, the use of di-
etary self-report measures may be methodologically limiting due to participants forgetting
to log items, or by including or excluding particular items to appear ‘healthier’. Methods
of dietary intake could be further improved by assessing urinary samples for polyphenolic
conjugate concentrations; however, urinary procedures would be highly intensive for a
sample of new mothers and may result in attrition. Methods that are more objective and
less intensive should be utilized; for example, logging food weights or recording items
via an app with the option to set reminders after meals. A further methodological im-
provement is the platform used to host the study questionnaires. Although user-friendly,
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Microsoft Forms had a cap on the number of questions allowed in one form, meaning the
study was split across two links. This, unfortunately, resulted in some missing data across
measures where participants did not submit Parts 1 or 2 correctly. Questionnaire software
that allows a large number of questions should be used in the future.
When investigating mood across a postnatal population it is important to consider
the biological changes that occur in pregnancy and in the immediate period after birth as
potential sensitive windows for nutritional intervention. For example, it is known that
a major brain change occurs in the immediate 5 days post-birth where a 43% increase
in monoamine oxidase A (MAO-A) is observed in mood-modulating brain areas during
postpartum blues (PPB) [58–62]. Severe PPB has been found to be a significant predictor of
later clinical PND [63,64] suggesting postnatal days 0–5 as prodromal for the subsequent
postnatal mood experience. Results from Dowlati et al. [65] show promising support
for nutritional intervention in this vulnerable period. Specifically, mothers consumed a
daily supplement containing 2 g tryptophan, 10 g tyrosine and 280 mL blueberry juice
(Milne Fruit Products) with blueberry extract (1 g VitaBlue) across postnatal days 3–5. On
day 5, mothers in the placebo group, who did not take a supplement, reported higher
depressed mood on a Visual Analog Scale (VAS) following a sad mood induction procedure
(MIP), whereas supplemented mothers showed no such effect. Such results imply that a
concoction of monoamine precursor amino acids and dietary antioxidants may counteract
mood disturbance in the PPB peak, which may reduce the likelihood of clinical PND.
Forthcoming trials should consider an intervention in the postnatal period closer to birth
where vulnerability to long-lasting mood change may be higher and should utilise a
higher number of participants to improve power and sensitivity to detect mood effects.
In addition, there is a need for more data on the natural course of depression and anxiety
throughout pregnancy and the postpartum period, and exploration into the effects of
nutritional intervention in the antenatal period is warranted. Thus, forthcoming research
should aim to explore mood effects in flavonoid-supplemented populations pre- and
postnatally to identify potential critical periods for positive mood change. In addition,
research containing measures of oxidative stress, BDNF regulation, or other physiological
markers would be informative alongside mood measurement to investigate the mechanistic
potential of flavonoids as therapeutic agents in reducing or preventing mood disorders.
In conclusion, this research adds to the growing body of literature implementing
flavonoids as beneficial dietary constituents for healthy mood. Specifically, this exploratory
study demonstrated alleviated feelings of state anxiety and improved perceived quality
of physical health in a community sample of 0–12-month postnatal mothers following a
2-week daily dietary flavonoid intervention.
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